Davion Healthcare Plc, an Irish-registered public company specializing in non-invasive medical technologies, today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed direct listing of its ordinary shares on the NASDAQ Global Market for which the ticker symbol “DAVI” has been reserved with NASDAQ.
Davion Healthcare Plc is not conducting an initial public offering and will not raise new capital in connection with this listing. The registration statement relates solely to the registration of existing ordinary shares held by current shareholders.
The proposed listing is expected to enhance visibility and liquidity for the company's shareholders while enabling broader access to U.S. investors.
The registration statement has been filed with the SEC but has not yet become effective. The ordinary shares may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our F-1 filed on August 4th, 2025. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Davion Healthcare Plc which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
A copy of the registration statement is available on the SEC's website at www.sec.gov.
About Davion Healthcare Plc
Davion Healthcare Plc (www.davionhealthcare.com) develops innovative, non-invasive diagnostic and monitoring solutions for home and clinical use, including its flagship non-invasive home test for breast anomalies, BreastCheck. Headquartered in Dublin, Ireland, the company is committed to advancing global access to affordable, effective medical technologies.
https://c212.net/c/img/favicon.png?sn=LN43581&sd=2025-08-04
View original content:https://www.prnewswire.com/news-releases/davion-healthcare-plc-files-registration-statement-for-proposed-direct-listing-on-nasdaq-302520892.html
SOURCE DAVION HEALTHCARE PLC
https://rt.newswire.ca/rt.gif?NewsItemId=LN43581&Transmission_Id=202508041216PR_NEWS_USPR_____LN43581&DateId=20250804